Stock Price & Analysis

Based on the provided data and current market conditions, here's a concise analysis of ISRG:

Technical Analysis

The stock closed at $592.64 on Friday, January 17, 2025, with a regular market percentage change of +1.47%. The stock has shown strong momentum, with RSI at 72.55 indicating overbought conditions in the near term.

Fundamental Strengths

• Strong preliminary Q4 revenue of $2.41B, exceeding consensus expectations of $2.2B
• Market leader in robotic surgery with significant market share
• Consistent earnings beats driven by robust product demand

Analyst Consensus

Wall Street maintains a Strong Buy rating with an average price target of $600.22, implying a modest 1.28% upside from current levels. Notable recent actions include:

• RBC Capital: Buy rating with $641 price target
• Bernstein: Buy rating with $700 price target
• Truist Securities: Strong Buy with $640 target

Technical Levels Key Fibonacci levels to watch [from provided data]:

• Resistance: R1 at $586.52, R2 at $603.59
• Support: S1 at $531.26, S2 at $514.19
• Pivot point: $558.89

Recommendation Given the stock's current overbought conditions and recent strong performance, it would be prudent to wait for a pullback toward the first support level around $531 before initiating new long positions. For existing holders, consider taking partial profits and maintaining a trailing stop loss below the first support level.

Based on the provided data and analysis, here is the price prediction for ISRG stock in 2025:

ISRG is expected to reach $650-675 by end of 2025, representing a 10-14% upside from current levels of $592.64. This projection is supported by:

1. Strong technical momentum with RSI at 72.55 indicating bullish sentiment, though slightly overbought. The stock has maintained an upward channel with higher lows and higher highs over the past 3 months.

2. Recent analyst upgrades including RBC Capital maintaining Buy rating with $641 target and Bernstein reiterating Buy with $700 target. The average analyst consensus price target is $600.22.

3. Fundamental growth drivers including continued adoption of robotic surgery systems globally. The company's da Vinci installed base grew to nearly 7,800 robots with procedures up 26% YoY in recent quarters.

The key catalyst will be the company's preliminary Q4 revenue of $2.41B beating consensus of $2.2B, demonstrating strong execution and market leadership in surgical robotics. While near-term volatility is possible given the overbought RSI, the long-term uptrend remains intact supported by expanding market opportunity and competitive advantages.

The S1 support level for ISRG Stock is $542.33 ,The R1 resistant level for ISRG Stock is $607.85.

As of the end of day on 2025-01-24, the price of ISRG Stock was $584.73.

The target price for ISRG Stock according to analyst rating is 587.14, with the highest price target at 655.00 and the lowest at 510.00. Analysts have a Strong Buy rating on ISRG Stock overall.

The market cap of ISRG is $208.0B.

Based on the provided data, here's a comprehensive analysis of ISRG's valuation:

Valuation Analysis ISRG currently trades at a P/E ratio of 78.95 (Q3 2024), significantly higher than the medical instruments industry average of 27.6. The stock's EV/EBITDA of 66.36 and P/S ratio of 22.52 also indicate premium valuations compared to industry peers.

Recent Performance The stock closed at $592.64 on January 17, 2025, with a regular market gain of 1.47%. The company recently reported preliminary Q4 revenue of $2.41B, exceeding consensus expectations of $2.2B, demonstrating strong business momentum.

Analyst Perspective RBC Capital maintains a Buy rating with a $641 price target, while the consensus is a Strong Buy with an average target of $600.22. This suggests limited upside potential from current levels despite the positive sentiment.

Conclusion ISRG appears overvalued based on five key factors:

1. Trading at nearly 3x the industry average P/E ratio
2. Premium EV/EBITDA multiple of 66.36x
3. Elevated P/S ratio of 22.52x
4. Current price near analyst consensus targets
5. Zero dividend yield despite mature business model

While the company shows strong operational execution, the current valuation multiples suggest the stock is priced for perfection and leaves little room for error.

Intuitive Surgical, Inc. develops, manufactures, and markets the da Vinci surgical system and the Ion endoluminal system. The Company's products and related services enable physicians and healthcare providers to access minimally invasive care. The da Vinci surgical system consists of a surgeon console or consoles, a patient-side cart, and a high-performance vision system. The da Vinci products fall into five categories, namely da Vinci surgical systems, da Vinci instruments and accessories, da Vinci Stapling, da Vinci Energy, and da Vinci Vision, including Firefly Fluorescence imaging systems and da Vinci Endoscopes. It also provides a comprehensive suite of systems, learning, and services offerings. The Ion endoluminal system consists of a system cart, a controller, a catheter, and a vision probe. It extends its commercial offerings beyond surgery into diagnostic procedures, enabling minimally invasive biopsies in the lung. Both systems use software, instruments, and accessories.

Based on the provided data and analysis, here is the price prediction for ISRG stock by 2030:

Intuitive Surgical (ISRG) stock is projected to reach $950-1000 by 2030, driven by its dominant 57% market share in robotic surgery and consistent earnings growth. The company's strong moat in surgical robotics technology and expanding applications of its da Vinci system support this bullish outlook. Recent analyst ratings show a Strong Buy consensus with near-term price targets around $600-700, indicating steady upward momentum.

ISRG has a total of 13676 employees.